NURIX THERAPEUTICS, INC. (NRIX) Free cash flow
- Free cash flow · 12 months (USD): Value $-304.53M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-05-31..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-05-31..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-05-31..
- Free cash flow margin · 12 months: Value -828.28%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-05-31..
Free cash flow
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-304.53M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-05-31. $-293.70M − $10.82M ≈ $-304.53M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -828.28% | (Operating cash flow − capital spending) / revenue. Period ending 2026-05-31. $-304.53M ÷ $36.77M × 100 ≈ -828.28% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-293.70M | Cash generated by operating activities. Period ending 2026-05-31. |
| Operating cash flow / net income · 12 months | 0.86× | Operating cash flow / net income. Period ending 2026-05-31. $-293.70M ÷ $-341.35M ≈ 0.86× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -293.70M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 10.82M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -304.53M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 36.77M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -341.35M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $-304.53M | (m) | $-293.70M | $10.82M | (m) | $36.77M | (m) | $-341.35M | (m) | (m) | -828.28% | 0.86× |
| 2026-02-28 | $-271.85M | (m) | $-260.29M | $11.56M | (m) | $71.78M | (m) | $-295.28M | (m) | (m) | -378.74% | 0.88× |
| 2025-11-30 | $-263.47M | (m) | $-249.47M | $14.00M | (m) | $83.98M | (m) | $-264.46M | (m) | (m) | -313.73% | 0.94× |
| 2025-08-31 | $-241.36M | (m) | $-230.38M | $10.98M | (m) | $83.69M | (m) | $-244.78M | (m) | (m) | -288.41% | 0.94× |
| 2025-05-31 | $-225.79M | (m) | $-215.18M | $10.61M | (m) | $88.38M | (m) | $-207.32M | (m) | (m) | -255.47% | 1.04× |
| 2025-02-28 | $-201.59M | (m) | $-191.72M | $9.87M | (m) | $56.42M | (m) | $-208.40M | (m) | (m) | -357.33% | 0.92× |
| 2024-11-30 | $-181.86M | (m) | $-172.58M | $9.27M | (m) | $54.55M | (m) | $-193.57M | (m) | (m) | -333.38% | 0.89× |
| 2024-08-31 | $-106.90M | (m) | $-97.14M | $9.75M | (m) | $56.42M | (m) | $-176.98M | (m) | (m) | -189.45% | 0.55× |
| 2024-05-31 | $-105.97M | (m) | $-96.10M | $9.87M | (m) | $62.30M | (m) | $-165.00M | (m) | (m) | -170.08% | 0.58× |
| 2024-02-29 | $-83.87M | (m) | $-74.86M | $9.01M | (m) | $80.89M | (m) | $-144.73M | (m) | (m) | -103.69% | 0.52× |
| 2023-11-30 | $-89.77M | (m) | $-81.36M | $8.40M | (m) | $76.99M | (m) | $-143.95M | (m) | (m) | -116.60% | 0.57× |
| 2023-08-31 | $-154.39M | (m) | $-146.01M | $8.38M | (m) | $68.61M | (m) | $-148.71M | (m) | (m) | -225.02% | 0.98× |
| 2023-05-31 | $-160.52M | (m) | $-151.18M | $9.34M | (m) | $60.94M | (m) | $-157.44M | (m) | (m) | -263.43% | 0.96× |
| 2023-02-28 | $-176.68M | (m) | $-165.63M | $11.05M | (m) | $41.69M | (m) | $-178.56M | (m) | (m) | -423.78% | 0.93× |
| 2022-11-30 | $-172.05M | (m) | $-159.81M | $12.24M | (m) | $38.63M | (m) | $-180.36M | (m) | (m) | -445.42% | 0.89× |
| 2022-08-31 | $-163.30M | (m) | $-152.76M | $10.54M | (m) | $39.24M | (m) | $-171.34M | (m) | (m) | -416.17% | 0.89× |
| 2022-05-31 | $-145.41M | (m) | $-136.43M | $8.99M | (m) | $38.70M | (m) | $-154.47M | (m) | (m) | -375.74% | 0.88× |
| 2022-02-28 | $-143.34M | (m) | $-135.05M | $8.29M | (m) | $34.36M | (m) | $-135.45M | (m) | (m) | -417.17% | 1.00× |
| 2021-11-30 | $-90.03M | (m) | $-84.36M | $5.66M | (m) | $29.75M | (m) | $-117.19M | (m) | (m) | -302.61% | 0.72× |
| 2021-08-31 | $-79.64M | (m) | $-73.94M | $5.71M | (m) | $29.04M | (m) | $-99.41M | (m) | (m) | -274.22% | 0.74× |
| 2021-05-31 | $-55.62M | (m) | $-50.10M | $5.51M | (m) | $22.88M | (m) | $-89.09M | (m) | (m) | -243.12% | 0.56× |
| 2021-02-28 | $-38.03M | (m) | $-33.00M | $5.03M | (m) | $19.97M | (m) | $-55.13M | (m) | (m) | -190.47% | 0.60× |
| 2020-11-30 | $-4.63M | (m) | $-80.00K | $4.55M | (m) | $17.82M | (m) | $-43.24M | (m) | (m) | -26.00% | 0.00× |
| 2020-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-05-31 | (m) | (m) | (m) | (m) | (m) | $19.49M | (m) | $-20.76M | (m) | (m) | (m) | (m) |
| 2020-02-29 | (m) | (m) | (m) | (m) | (m) | $24.75M | (m) | $-31.41M | (m) | (m) | (m) | (m) |
| 2019-11-30 | $-1.05M | (m) | $601.00K | $1.65M | (m) | $31.11M | (m) | $-21.70M | (m) | (m) | -3.37% | -0.03× |
| 2019-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |